Unraveling the Fallout of a Controversial Cancer Treatment

The story of Gleevec, a personalized medicine used to treat chronic myelogenous leukemia, highlights the potential and pitfalls of precision medicine. Gleevec's success in targeting a specific genetic abnormality led to high hopes for personalized medicine, but its exorbitant pricing and subsequent price hikes have raised concerns about the financial burden on patients. While Gleevec revolutionized the treatment of a rare cancer, the reality is that most diseases do not have a simple genetic cause, and the cost of personalized therapies for rare diseases remains astronomical. The story of Gleevec serves as a cautionary tale about the limitations and financial realities of personalized medicine.